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Low-Dose Cyproterone Acetate Treatment 
of Sexual Acting Out in Men With Dementia 
PETER HAUSSERMANN, DAVID GOECKER, KLAUS BEIER, AND STEFAN SCHROEDER 
ABSTRACT. Increased sexual activity in patients with dementia is problematic for caregivers 
and has no proven treatment. This report describes two male patients who had dementia 
with pronounced sexual acting out. One patient had vascular dementia and the other patient 
had Parkinson’s disease with associated dementia. After nonresponse to neuroleptics and 
sedatives, low-dose cyproterone acetate successfully reduced sexual acting out without rel- 
evant side effects in both patients. 
KEYWORDS: Sexual acting out; dementia; antiandrogen; cyproterone acetate 
Different disciplines, from psychiatry to 
general medicine, are nowadays faced 
with treating dementia patients. Neu- 
ropsychiatric symptoms such as 
depression, hallucinations, and agitated 
behavior contribute most to carers’ bur- 
den (Assal & Cummings, 2002; Krueger 
& Kaplan, 2000). The frequency of dis- 
ruptive sexual behavior in dementia 
patients has been shown to vary from 
4% to 14% (Kuhn et al., 1998). Increased 
sexual activity has been reported in 
patients with epilepsia, Parkinson’s dis- 
ease (Beier et al., 2000; Vogel & Schiffter, 
1983), traumatic brain injury (Miller et 
al., 1986), multiple sclerosis, and stroke 
(Monga et al., 1986). Sexual acting out 
has been demonstrated to be related to 
temporal and frontal lobe involvement 
(Absher et al., 2000) as well as to basal 
ganglia (Absher et al., 2000), cingulate 
cortex, or amygdaloid nucleus lesions 
(Absher et al., 2000; Monga et al., 1986). 
Sexual acting out may be manifested by 
an increased libido or sexual disinhibition 
(Miller et al., 1986; Rosler & Witztum, 
2000). In dementia, it has to be regarded 
as beyond the person’s understanding 
and control, not as a personal preference 
or willful behavior. There is no proven 
treatment (Miller et al., 1986), although 
reports have described reduction of 
increased sexual activity using pharma- 
cotherapy and behavioral/environmental 
(see Table 1) interventions (Cooper, 1987; 
Cooper et al., 1972; Levitsky & Owens, 
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1999). Putative antiandrogen antilibidinal 
medications include cyproterone acetate 
(CPA), flutamide, medroxyprogesterone 
acetate (MPA), CnRH-analogues, estro- 
gen, spironolactone, ketoconazole, and 
cimetidine (Lardinois & Mazzaferri, 1985; 
Rosler & Witztum, 2000; Wiseman et al., 
2000). Serotonergic substances have 
been shown to decrease delusions and 
irritability associated with hypersexual 
behavior (Stein et al., 1992; Stewart & 
Shin, 1997). 
PATIENTS AND METHODS 
A systematic study of the treatment of 
increased sexual activity in patients with 
dementia has not been reported. There- 
fore, our purpose was to evaluate the 
impact of CPA, a hormonal hydroxyprog- 
esterone derivative with a competitive 
antagonism in the androgen receptor in 
patients with dementia that exhibited 
sexual acting out. Caregivers and doc- 
tors recorded sexual behaviors and 
determined the degree of improvement 
after antiandrogen therapy. Caregivers 
consented to CPA treatment. Severity of 
dementia was scored using the Mini- 
Mental State Examination (MMSE). 
Case A 
Patient A, a 79-year-old male retired 
entrepreneur, has had a bipolar affective 
disorder since 1970, akinetic-rigid 
Parkinson’s disease since 1984, and 
slowly progressive cognitive deficits 
since 1989. A computed tomographic 
(CT) scan showed slight cortical brain 
atrophy in 1989. Initially, mainly his 
short-term memory was affected. Cogni- 
tive status further deteriorated and 
Parkinson’s disease-associated dementia 
was diagnosed in 1998, when the patient 
scored 22/30 on the MMSE and was 
impaired both in activities of daily living 
as well as in social functioning. 
On admission in 2000, his wife report- 
ed (auto)-sexual activity over several 
months. On the  gerontopsychiatric 
ward, he masturbated in front of female 
patients and nursing staff several times 
a week. No clear association to a manic 
episode could be found. There were also 
verbal components with sexual intent. 
In his MMSE on admission, he scored 19 
out of 30 points. His medication consist- 
ed of valproate (1,500 mg/day), olanza- 
pine (7.5 mg/day), lithium (800 mg/day), 
lorazepam (1 mg/day), and L-Dopa (250 
mg/day). Masturbation in public dra- 
matically diminished within a few days 
when he was placed on 10 mg CPA per 
day. A dose reduction of CPA to 5 mg per 
day was twice followed by a relapse of 
sexual acting out. After the dosage was 
reincreased to  10 mg per day, the symp- 
toms of agitated sexual behavior disap- 
peared. 
Case B 
Patient B, a 74-year-old male retired 
business consultant, was admitted to 
the psychogeriatric ward because of 
delusional misidentifications, visual 
and acoustic hallucinations, increased 
sexual appetence towards his wife, and 
compulsive masturbation with ejacula- 
tions in public and private places. 
Four years prior to admission, he had 
had several transitory ischemic attacks. 
The patient had a long-standing history 
of arterial hypertension with bad control 
of blood pressure. Further medical con- 
ditions included type I1 diabetes mellitus 
treated with insulin and cardiac arrhyth- 
mia with intermittent atrial fibrillation 
and sick sinus syndrome. Therefore, the 
patient received a pacemaker. A CT scan 
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TABLE 1. Putative Treatment Approaches for Sexual Acting Out in Patients 
With Dementia 
I .  Nonpharmacological Environmental interventions 
Nursing strategies 
Psychotherapy 
6 Carbamazepine 200-600 mg/day 
SSRIs: e.g., paroxetine 20 mg/day (Leo & Kim, 1995), fluoxetine 
Tricyclic antidepressants: clomipramine 75-1 50 mg/day (Leo 







Quetiapine 50-100 mg/day 
Risperidone 0.5-1 mg/day 
Melperone 50-100 mg/day 
Olanzepine 5-1 0 mg/day 
Hormonal antiandrogens 
Cyproterone acetate 10-300 mg/day (Cooper, 1987; Levitsky & 
Owens, 1999) 
Spironolactone 75 mg/day (Wiseman et al., 2000) 
Nonhormonal antiandrogens 
Medroxyprogesterone acetate 200-300 mg/week 
Cimetidine 600-1,600 mg/day (Wiseman et al., 2000) 
Ketoconazole 100-200 mg/day (Wiseman et al., 2000) 
Estradiol2 mg/day (Flynn, 1999) 
Conjugated estrogens 1.25 mg/day (Flynn, 1999) 
intramuscularly (Cooper, 1987) 
7, GnRH analogues Leuprolide 11.25 mg every 3 months subcutaneously 
(Levitsky & Owens, 1999) 
Note. SSRIs = selective serotonin reuptake inhibitors. 
performed at  that time showed moder- 
ate periventricular leucoaraiosis but no 
lacunar infarcts. 
Three months prior t o  hospital 
admission, he had a severe head trauma 
after a car accident with consecutive 
intracerebral hemorrhage in the right 
frontal lobe and right-sided subdural 
hematoma. According to his wife, there 
was a continuous cognitive decline over 
the preceding years but no inappropri- 
ate sexual behavior. 
On admission, his MMSE score was 
8/30. There were no frontal release signs 
or changes in dietary habits. A CT scan 
showed periventricular leucoaraiosis, 
global brain atrophy, and lacunar infarcts 
in both temporal lobes and the left occip 
ital cortex. 
Psychopharmacotherapy consisted of 
valproate (300 mg/day), mirtazepine (45 
mg/day), and risperidone (1 mg/day). 
After 1 week in the hospital, we started 
the application of 10 mg CPA/day and 
sexually inappropriate behavior disap- 
peared within a few days. Again, a dose 
reduction of CPA to  5 mg per day was fol- 
lowed by a relapse of sexual acting out. 
184 P Haussermann et al. 
After the dosage was reincreased to 10 
mg per day, the symptoms of sexual act- 
ing out disappeared. The patient was fol- 
lowed up for 6 months and there was no 
relevant change in his poor cognitive sta- 
tus. On his MMSE 9 months after the 
accident, he scored 8/30 points. 
The patient was diagnosed as having 
vascular dementia after traumatic intra- 
cerebral hemorrhage. Neuroimaging 
showed periventricular leucoaraiosis as 
well as multiple lacunar infarcts and 
brain atrophy. Dementia diagnosis was 
based on neuroimaging findings, both 
impairment in his activities and experi- 
ences of daily living (personal hygiene, 
dressing, eating) as well as impaired 
social functioning. Formal neuropsycho- 
logical testing was difficult to perform 
because of severe attention deficits and 
lack of cooperation. Tower of Hanoi test- 
ing was not possible; neither was the use 
of other standardized neuropsychologi- 
cal tests evaluating frontal lobe function. 
There was reduced attentional span, and 
cognitive speed was severely impaired. 
Both short-term memory and long-term 
memory were deficient. 
DISCUSSION 
It  should be noted that in Patient A, 
increased sexual activity interpreted as 
a complication of dopaminergic thera- 
py in Parkinson’s disease seems 
improbable (Beier et  al., 2000), though 
it cannot be fully excluded (Vogel & 
Schiffter, 1983). Head trauma with 
frontal lobe hemorrhage may at  least 
partially account for increased sexual 
activity seen in Patient B (Miller et al., 
1986; Monga et  al., 1986), even in the 
absence of frontal release signs o r  
dietary changes. 
Our two cases suggest that CPA given 
in a low dose-less than a tenth of the 
usually recommended dose-may be 
useful to reduce sexually inappropriate 
behavior in men with dementia. For the 
treatment of paraphilias (Rosler & Witz- 
tum, 2000) in younger patients, antian- 
drogen therapy may include MPA and 
CPA. MPA can be administered at 300 
mg per week intramuscularly, while CPA 
can be given in daily oral doses 
between 50 and 100 mg or 300 mg intra- 
muscularly weekly (Briken et al., 2000). 
The only data supporting the use of 
antiandrogen therapy for the treatment 
of hypersexuality or  paraphilias in 
older patients with dementia are in the 
form of case reports. The patients were 
administered MPA 300 mg per week 
intramuscularly for 1 year. Alternative- 
ly, 10 to 100 mg of CPA can be given 
daily (Cooper, 1987; Levitsky & Owens, 
1999), depending on tolerability and 
side effects. 
The mechanisms underlying response 
to lowdose CPA in these two dementia 
patients are difficult to elucidate. Major 
factors might be the known lower testos- 
terone blood levels in elderly patients 
and pharmacokinetic changes associat- 
ed with aging, i.e., longer plasma half-life 
and relatively higher CPA levels (Krueger 
& Kaplan, 2000; Levitsky &Owens, 1999). 
Pharmacodynamic changes with 
increased receptor sensitivity may as 
well be important in elderly (dementia) 
patients (Bradford, 2001). Neurotrans- 
mitter changes within hypothalamic and 
frontal loops involved in the control of 
libido and sexual activity that occur in 
normal aging as well as in the course of 
dementia may also contribute to low- 
dose CPA response seen in both patients 
(Bradford, 2001). 
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Our observation has limitations, includ- 
ing a potential recall bias by the patient’s 
caregivers during follow-up, and the s u b  
jective nature of responses. We would like 
to emphasize the putative ethical and 
legal implications of CPA pharmacothera- 
py, mainly concerning the inability of 
dementia patients to consent to pharma- 
cotherapy and the possible side effects, 
including liver dysfunction, carcinogenic 
effects, osteoporosis, depression, or 
gynecomastia. CPA may also be used for 
the treatment of female hypersexuality 
(Mellor et al., 1988). 
In conclusion, the prescription of CPA 
was helpful in the treatment of our 
patients who demonstrated sexual acting 
out. After nonresponse to  conventional 
psychopharrnacotherapy (sedatives, 
neuroleptics, and valproate), the pre- 
scription of lowdose CPA reduced sexual 
acting out significantly in both patients 
without relevant side effects. Subjective- 
ly, intensity of increased sexual activity in 
both patients decreased to the point that 
it was no longer considered problematic 
by the caregivers. Objectively, the fre- 
quency of (auto)-sexual activity 
decreased significantly. 
Nevertheless, there are no systemat- 
ic studies available today concerning 
the treatment of inappropriate sexual 
behavior in dementia. Prospective dou- 
ble-blind studies that clearly define 
response variables and focus on long- 
term side effects are needed t o  confirm 
our observations. 
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